Strategic Partnerships Oncodesign Services has a track record of forming strategic collaborations, including a recent France-based in vitro/in vivo partnership and prior licensing and supply agreements. Target potential: biopharma companies seeking integrated preclinical support and access to specialized imaging, radiopharmaceutical, and translational study capabilities.

Expansion & Leadership New executive leadership appointed in 2025 suggests a strategic push to expand market presence and strengthen client trust. Target outreach to mid-to-large biotech firms expanding their preclinical pipelines who value experienced leadership and proven CRO operationsacross oncology, immuno-oncology, and inflammatory diseases.

Mature Capabilities Longstanding expertise in preclinical oncology, imaging, radiopharmaceuticals, and translational pharmacology with AAALAC accreditation. Position as a full-spectrum preclinical partner for programs approaching IND enabling studies and complex imaging needs for longitudinal data.

Targeted Focus Specialization in targeted radiotherapy, immuno-oncology, and inflammatory diseases aligns with high-growth therapeutic areas. Sales angle: offer integrated study design and mechanism-of-action validation to de-risk go/no-go decisions for IND progression.

Digital & Reach Tech stack indicates active digital marketing and analytics use, including LinkedIn Ads, Microsoft Advertising, and Pardot. Leverage digital channels and case studies to reach decision-makers at early-stage and mid-stage biotechs seeking preclinical acceleration and evidence-backed IND readiness.